Clinical trials: Food Safety
Healthy Participants
A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects
This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-890 Tablets in Healthy Chinese Subjects
- Trial name
- NCT06506591
- Testing
- WD-890
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese…
- Trial name
- NCT06144697
- Testing
- BMS-986465, Pegasys, Famotidine
- Where
- 2 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes
This 12 week placebo-controlled study evaluates the safety and impact of 2 different strengths of the medical food formulation WBF-0011.
- Trial name
- NCT04047537
- Testing
- Medical Food Formulation 1, Medical Food Formulation 2
- Where
- Ireland
- Volunteers
- 41 people
- Sponsor
- Pendulum Therapeutics
Healthy
A Multiple-Dose Study of LY3502970 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states.
- Trial name
- NCT05110794
- Testing
- LY3502970
- Where
- Singapore
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hereditary Angioedema
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
This is a 3 part phase 1, randomized, double-blind, placebo-controlled, study of the safety, tolerability, and pharmacokinetics of KVD824 following administration of single and multiple ascending oral doses; followed by a…
- Trial name
- NCT05178355
- Testing
- KVD824
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Normal, Healthy Volunteers
A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.
- Trial name
- NCT01744808
- Testing
- EB-1020 IR, EB-1020 SR1, EB-1020 SR2
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diopathic Pulmonary Fibrosis, Pulmonary Fibrosis
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions.
- Trial name
- NCT06160440
- Testing
- SC1011
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Tuberculosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants
This first time in human (FTIH) study assesses the safety, tolerability, and pharmacokinetics (PK) of single and multiple increasing doses of GSK2556286.
- Trial name
- NCT04472897
- Testing
- GSK2556286
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peanut-Induced Anaphylaxis, Peanut Allergy
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies.
- Trial name
- UKK-0018 (NCT07349212)
- Testing
- UKK-0018
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 40 people
- Sponsor
- Ukko Inc
Healthy
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body).
- Trial name
- NCT00689039
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Food Allergy
Open-label Extension Study of ADP101
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
- Trial name
- NCT05243719
- Testing
- ADP101
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Healthy, Peripheral Neuropathic Pain
Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750
This is an exploratory, randomised, double-blind, placebo-controlled, Phase I study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food-effect of single and multiple, ascending oral doses of TRK-750 in…
- Trial name
- NCT03346330
- Testing
- TRK-750
- Where
- United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Toray Industries, Inc
Healthy
This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.
The primary objective of the single-rising dose (SRD) part (trial part 1) is to investigate the safety and tolerability of BI 730460 in healthy subjects following oral administration of single rising doses.
- Trial name
- NCT03483077
- Testing
- BI 730460
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649. The pharmacodynamic activity of PF-06743649 will also be assessed.
- Trial name
- NCT02151617
- Testing
- PF-06743649
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
This is a single center,double-blind,randomized,parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of ZSP1273,and the effect of food on ZSP1273 Pharmacokinetics.
- Trial name
- NCT03679143
- Testing
- ZSP1273 100 mg, ZSP1273 200 mg, ZSP1273 400 mg
- Where
- China
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA).
- Trial name
- PROTECT (NCT05476497)
- Testing
- VLP Peanut
- Where
- 10 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Idiopathic Pulmonary Fibrosis
To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers
The pharmacokinetics (PK) and safety of single oral dose of DWN12088 in healthy adults will be compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat meal.
- Trial name
- NCT04767815
- Testing
- Diet A group, Diet B group, Diet C group
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Participants
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed
- Trial name
- NCT06897813
- Testing
- WD-910 tablet
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
High Risk Coronary Artery Disease
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability…
- Trial name
- NCT02963116
- Testing
- AZD5718 IR tablet, AZD5718 oral suspension, Rosuvastatin tablet
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca